High Dividend US Stocks in the Healthcare Sector (QCOR, AEGR, ARQL, DYAX)

New York, NY -- (SBWIRE) -- 10/16/2012 -- Questcor Pharmaceuticals, Inc.(NASDAQ:QCOR) shares climbed 5.32% and closed at $23.18 in the previous trading session. The company announced that it will release third quarter 2012 financial results on Tuesday, October 23, 2012 after the close of the U.S. financial markets. The Company will host a conference call and slide presentation via webcast on Tuesday, October 23, 2012 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and highlights of the quarter, as well as current corporate developments.It traded up as well, increasing 6.47 percent to $24.68 following the declaration of some insider trades made after the bell Monday.

Will QCOR Rebound After Today’s Slump? Find Out Here

Aegerion Pharmace (NGM:AEGR) is +1.19 - +6.82% from the previous close of $17.46. It traded between $18.26 - 19.25 with total traded volume of 712029 shares. Keep a close eye on AEGR, as the stock has been showing unusual moves over the past weeks. At Current market price, AEGR has recovered +58.72% from its 52-week Low of 11.75 and has Pulled back +2.42% from its 52-week high of 18.21.Aegerion Pharmaceuticals Inc.'s (AEGR, $18.69, +$1.23, +7.04%) own lead drug candidate. Kynamro heads before a panel of non-FDA experts Thursday charged with recommending approval of the drug and their FDA briefing shows an "unexpected" level of concern at the agency regarding its potential carcinogenicity, Needham's Chad Messer tells Dow Jones. That's good news for Aegerion, whose drug is being considered by the same panel tomorrow and got a boost yesterday from a surprisingly positive thinking at the FDA.The shares jumped 9.40% and closed at $17.46 in the last trading session after Reuters reported that U.S. drug reviewers were positive on Aegerion Pharmaceuticals Inc’s experimental drug for lipid disorder and said it showed a greater reduction in bad cholesterol as compared with statins, according to documents posted by the Food and Drug Administration on its website on October15, 2012. The FDA said an approval of the drug would require a risk evaluation and mitigation strategy to ensure that the benefits of lomitapide outweigh the risk of serious liver injury.

How Should Investors React To AEGR Now? Check here

New York, NY- ArQule, Inc. (NGM:ARQL) is very active today and traded between $2.74 - 2.92 with total traded volume of 785423 shares. At a current price of 2.84, ARQL is +0.19 - +7.17% from the previous close of $2.65. Moreover, At Current Market Price, ARQL is in distance of -38.33% from its 50-day Moving Average price of $4.6051 and -52.66% from its 200-day Moving Average price of $5.9994.ArQule Inc. (ARQL) has reached an agreement with the U.S. Food and Drug Administration to design a late-stage trial of its drug Tivantinib in patients with a type of liver cancer.Shares popped 8.7% to $2.88 in recent premarket trading. The stock was off 53% in the past 12 months. The biotechnology company, which focuses on small-molecule cancer therapeutics, said the Special Protocol Assessment agreement with the FDA is for the design of a pivotal Phase 3 trial, which will take the form of a randomized, double-blind study of Tivantinib in previously treated patients with MET diagnostic-high inoperable hepatocellular carcinoma.

Can ARQL Find The Top further? Find Out Here

Dyax Corp. (NGM:DYAX) reported EPS of -0.43. For the Current Fiscal year, the company is expected to report EPS of -0.35. For the Next Quarter and Next Year, the company is expected to report EPS of -0.08 and -0.14 respectively. At Current Market Price, DYAX is in distance of +21.08% from its 50-day Moving Average price of $2.4611 and +39.04% from its 200-day Moving Average price of $2.1433.Dyax Corp (NASDAQ:DYAX) augmented 12.18% to $2.67 on a traded volume of 244k shares.Last month, Dyax Corpand Kadmon Corporationentered into a strategic licensing agreement in which Kadmon has been granted an exclusive worldwide license for the development and commercialization of the fully human monoclonal antibody DX-2400. Under the terms of the agreement, Dyax will receive an upfront paymentand is eligible for significant development and commercial milestone payments.

Are these stocks a buy or sell? Let us help you decide, Check here

DISCLAIMER:

Neither PennyStocksUpdate.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by PennyStocksUpdate.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. PennyStocksUpdate.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through PennyStocksUpdate.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..

Contact:
PennyStocksUpdate.com
info@pennystocksupdate.com